ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2020Guideline
- Seroprevalence of hepatitis C antibodies in pregnant women in the state of Paraná, Brazil.Clinics (Sao Paulo, Brazil) · 2026Article
- Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Recent Advances in the Epidemiology, Screening, and Management of Hepatitis C Virus Infection in Pregnancy.Gastroenterology & hepatology · 2026Article
- Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US.Viruses · 2026Article
- Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Cost-Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- A scoping review on HCV screening strategies: population to screen and the test types.BMC public health · 2025Article
- Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egypt: a cost-effectiveness study.BMJ public health · 2024Article
- Hepatitis C virus detection and management after implementation of universal screening in pregnancy.AJOG global reports · 2024Article
- Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Trends in the Prevalence of Hepatitis C Infection During Pregnancy and Maternal-Infant Outcomes in the US, 1998 to 2018.JAMA network open · 2023Article
- Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Congenital Co-infections Among HIV-Exposed Infants Born to Mothers on Antiretroviral Treatment in the United States.Frontiers in pediatrics · 2022Article
- Management of in- and out-of-hospital screening for hepatitis C.Frontiers in public health · 2022Review
- Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises.Diagnostics (Basel, Switzerland) · 2021Review
- Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy.JHEP reports : innovation in hepatology · 2021Article
- Innovations in Hepatitis C Screening and Treatment.Hepatology communications · 2021Review
- Viral hepatitis and pregnancy.Nature reviews. Gastroenterology & hepatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundHepatitis C virus' (HCV) chronic prevalence among pregnant women in the United States doubled nationally from 2009-2014 (~0.7%), yet many cases remain undiagnosed. Screening pregnant women is not recommended by the Society of Maternal-Fetal Medicine or the Centers for Disease Control and Prevention, despite new American Association For the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidelines recommending screening for this group. We assessed the cost-effectiveness of HCV screening for pregnant women in the United States.
methodsAn HCV natural history Markov model was used to evaluate the cost-effectiveness of universal HCV screening of pregnant women, followed by treatment after pregnancy, compared to background risk-based screening from a health-care payer perspective. We assumed a HCV chronic prevalence of 0.73% among pregnant women, based on national data. We assumed no Medicaid reimbursement restrictions by fibrosis stage at baseline, but explored differing restrictions in sensitivity analyses. We assessed costs (in US dollars) and health outcomes (in quality-adjusted life-years [QALYs]) over a lifetime horizon, using new HCV drug costs of $25 000/treatment. We assessed mean incremental cost-effectiveness ratios (ICERs) under a willingness-to-pay threshold of $50 000/QALY gained. We additionally evaluated the potential population impact.
resultsUniversal antenatal screening was cost-effective in all treatment eligibility scenarios (mean ICER <$3000/QALY gained). Screening remained cost-effective at a prevalence of 0.07%, which is the lowest estimated prevalence in the United States (in Hawaii). Screening the ~5.04 million pregnant women in 2018 could result in the detection and treatment of 33 000 women, based on current fibrosis restrictions.
conclusionsUniversal screening for HCV among pregnant women in the United States is cost-effective and should be recommended nationally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.